Genprex (NASDAQ:GNPX) Trading Up 3.8% – Here’s What Happened

Genprex (NASDAQ:GNPX)’s stock price was up 3.8% on Monday . The stock traded as high as $0.6854 and last traded at $0.6710. Approximately 192,953 shares were traded during mid-day trading, a decline of 23% from the average daily volume of 249,396 shares. The stock had previously closed at $0.6467.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on GNPX shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Genprex in a report on Tuesday, April 21st. Wall Street Zen raised shares of Genprex from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Genprex presently has a consensus rating of “Sell”.

Genprex Stock Down 4.4%

The firm has a market cap of $6.95 million, a PE ratio of -0.04 and a beta of -0.98. The company’s fifty day moving average price is $0.99 and its two-hundred day moving average price is $1.84.

Genprex (NASDAQ:GNPX) last issued its earnings results on Wednesday, May 13th. The company reported ($0.64) earnings per share for the quarter.

Institutional Trading of Genprex

Institutional investors have recently added to or reduced their stakes in the stock. Mayflower Financial Advisors LLC purchased a new stake in Genprex during the first quarter worth about $36,000. Manchester Financial Inc. purchased a new stake in Genprex during the first quarter worth about $36,000. Finally, Susquehanna International Group LLP boosted its holdings in Genprex by 11.7% during the third quarter. Susquehanna International Group LLP now owns 340,056 shares of the company’s stock worth $58,000 after buying an additional 35,661 shares in the last quarter. Hedge funds and other institutional investors own 14.05% of the company’s stock.

About Genprex

Genprex, Inc is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.

In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes.